Free Trial
→ Why I went to Mount Rushmore (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Daxor Corporation stock logo
DXR
Daxor
$10.41
-0.5%		$10.60
$8.56
▼
$14.76
$61.07M0.3539,172 shs7,459 shs
Femasys Inc. stock logo
FEMY
Femasys
$2.00
-2.4%		$2.60
$1.92
▼
$22.20
$17.13M-2.1684,830 shs128,263 shs
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
$5.95
+3.8%		$5.33
$9.41
▼
$13.80
$66.71M0.09205,918 shs229,318 shs
RenovoRx, Inc. stock logo
RNXT
RenovoRx
$1.28
-3.8%		$1.56
$0.70
▼
$2.59
$60.02M0.98618,175 shs797,991 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Daxor Corporation stock logo
DXR
Daxor
-0.36%-1.98%-3.25%+1.26%-20.41%
Femasys Inc. stock logo
FEMY
Femasys
-2.44%-2.44%-29.33%-49.87%-83.25%
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
0.00%-10.87%+4.24%+41.85%+107.33%
RenovoRx, Inc. stock logo
RNXT
RenovoRx
-3.76%-18.99%-36.00%+37.62%+5.79%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Daxor Corporation stock logo
DXR
Daxor
$10.41
-0.5%		$10.60
$8.56
▼
$14.76
$61.07M0.3539,172 shs7,459 shs
Femasys Inc. stock logo
FEMY
Femasys
$2.00
-2.4%		$2.60
$1.92
▼
$22.20
$17.13M-2.1684,830 shs128,263 shs
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
$5.95
+3.8%		$5.33
$9.41
▼
$13.80
$66.71M0.09205,918 shs229,318 shs
RenovoRx, Inc. stock logo
RNXT
RenovoRx
$1.28
-3.8%		$1.56
$0.70
▼
$2.59
$60.02M0.98618,175 shs797,991 shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Daxor Corporation stock logo
DXR
Daxor
-0.36%-1.98%-3.25%+1.26%-20.41%
Femasys Inc. stock logo
FEMY
Femasys
-2.44%-2.44%-29.33%-49.87%-83.25%
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
0.00%-10.87%+4.24%+41.85%+107.33%
RenovoRx, Inc. stock logo
RNXT
RenovoRx
-3.76%-18.99%-36.00%+37.62%+5.79%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Daxor Corporation stock logo
DXR
Daxor
2.50
Moderate BuyN/AN/A
Femasys Inc. stock logo
FEMY
Femasys
2.50
Moderate Buy$50.002,400.00% Upside
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
0.00
N/AN/AN/A
RenovoRx, Inc. stock logo
RNXT
RenovoRx
2.75
Moderate Buy$8.50564.06% Upside

Current Analyst Ratings Breakdown

Latest FEMY, HSAQ, RNXT, and DXR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
Daxor Corporation stock logo
DXR
Daxor
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C)
9/2/2026
RenovoRx, Inc. stock logo
RNXT
RenovoRx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
8/18/2026
RenovoRx, Inc. stock logo
RNXT
RenovoRx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/18/2026
Femasys Inc. stock logo
FEMY
Femasys
Lake Street Capital logo
Lake Street Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$10.00
8/17/2026
Femasys Inc. stock logo
FEMY
Femasys
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
8/14/2026
Femasys Inc. stock logo
FEMY
Femasys
Maxim Group logo
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$10.00
7/31/2026
Femasys Inc. stock logo
FEMY
Femasys
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
RenovoRx, Inc. stock logo
RNXT
RenovoRx
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/16/2026
Femasys Inc. stock logo
FEMY
Femasys
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Daxor Corporation stock logo
DXR
Daxor
N/AN/AN/AN/AN/AN/A
Femasys Inc. stock logo
FEMY
Femasys
$2.30M7.28N/AN/A$2.01 per share1.00
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
N/AN/AN/AN/A($0.62) per shareN/A
RenovoRx, Inc. stock logo
RNXT
RenovoRx
$1.98M29.23N/AN/A$0.15 per share8.53
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Daxor Corporation stock logo
DXR
Daxor
N/AN/AN/AN/AN/AN/AN/AN/AN/A
Femasys Inc. stock logo
FEMY
Femasys
-$18.63M-$3.53N/AN/AN/A-534.36%-225.97%-74.68%11/17/2026 (Estimated)
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
-$380KN/AN/AN/AN/AN/AN/A-2.38%N/A
RenovoRx, Inc. stock logo
RNXT
RenovoRx
-$11.17M-$0.31N/AN/AN/A-621.71%-135.11%-101.91%11/12/2026 (Estimated)

Latest FEMY, HSAQ, RNXT, and DXR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Femasys Inc. stock logo
FEMY
Femasys
-$1.31-$1.33-$0.02-$1.33$0.73 million$0.33 million
8/12/2026Q2 2026
RenovoRx, Inc. stock logo
RNXT
RenovoRx
-$0.0725-$0.05+$0.0225-$0.06$0.70 million$0.91 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Daxor Corporation stock logo
DXR
Daxor
N/AN/AN/AN/AN/A
Femasys Inc. stock logo
FEMY
Femasys
N/AN/AN/AN/AN/A
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
N/AN/AN/AN/AN/A
RenovoRx, Inc. stock logo
RNXT
RenovoRx
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Daxor Corporation stock logo
DXR
Daxor
N/AN/AN/A
Femasys Inc. stock logo
FEMY
Femasys
0.89
2.14
0.55
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
N/A
0.17
0.61
RenovoRx, Inc. stock logo
RNXT
RenovoRx
N/A
5.74
5.53

Institutional Ownership

CompanyInstitutional Ownership
Daxor Corporation stock logo
DXR
Daxor
1.34%
Femasys Inc. stock logo
FEMY
Femasys
65.27%
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
89.71%
RenovoRx, Inc. stock logo
RNXT
RenovoRx
3.10%

Insider Ownership

CompanyInsider Ownership
Daxor Corporation stock logo
DXR
Daxor
51.50%
Femasys Inc. stock logo
FEMY
Femasys
7.75%
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
21.90%
RenovoRx, Inc. stock logo
RNXT
RenovoRx
9.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Daxor Corporation stock logo
DXR
Daxor
375.84 million2.83 millionNot Optionable
Femasys Inc. stock logo
FEMY
Femasys
548.38 million7.73 millionNot Optionable
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
411.21 million8.76 millionNot Optionable
RenovoRx, Inc. stock logo
RNXT
RenovoRx
1745.13 million40.89 millionNot Optionable

Recent News About These Companies

RenovoRx Advances TAMP into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
October 8 at 7:29 PM  |  marketscreener.comM
RenovoRx Enrolls First Patient In UVM-Sponsored Pancreatic Cancer PRISM-TAMP Trial
October 8 at 9:28 AM  |  rttnews.comhttps://www.rttnews.com/3697465/renovorx-enrolls-first-patient-in-uvm-sponsored-pancreatic-cancer-prism-tamp-trial.aspx
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial
October 7 at 8:30 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/07/3376461/0/en/renovorx-advances-tamp-into-borderline-resectable-pancreatic-cancer-with-first-patient-enrolled-in-investigator-initiated-prism-tamp-trial.html
Medline (NASDAQ:MDLN) versus RenovoRx (NASDAQ:RNXT) Head-To-Head Comparison
October 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31086063
RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3372883/0/en/renovorx-announces-peer-reviewed-publication-highlighting-the-tamp-platform-s-potential-to-improve-chemotherapeutic-delivery-for-locally-advanced-pancreatic-cancer.html
RenovoRx, Inc. (NASDAQ:RNXT) Stock Short Interest Jumps 55.7%
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-renovorx-inc-nasdaq-rnxt-stock-short-interest-jumps-557-2026-10-01/
RenovoRx, Inc. (NASDAQ:RNXT) Short Interest Update
September 17, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-renovorx-inc-nasdaq-rnxt-short-interest-update-2026-09-17/
RenovoRx HC Wainwright presentation to highlight RenovoCath growth and Phase III TIGeR-PaC timeline
September 2, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/renovorx-hc-wainwright-presentation-to-highlight-renovocath-growth-and-phase-iii-tiger-pac-timeline/ar-AA2bq7iJ
RenovoRx to Present at H.C. Wainwright 28th Annual Global Investment Conference, September 14th-16th
September 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/02/3355141/0/en/renovorx-to-present-at-h-c-wainwright-28th-annual-global-investment-conference-september-14th-16th.html
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced ...
August 25, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/renovorx-highlights-peer-reviewed-publication-123000519.html
RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform's Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
August 25, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/25/3350436/0/en/renovorx-highlights-peer-reviewed-publication-of-pharmacokinetic-and-pharmacodynamic-pk-pd-data-supporting-tamp-platform-s-targeted-drug-delivery-in-locally-advanced-pancreatic-can.html
RenovoRx (NASDAQ:RNXT) Gains Attention After Compliance Update
August 21, 2026  |  kalkinemedia.comK
RenovoRx regains Nasdaq compliance
August 21, 2026  |  msn.comhttps://www.msn.com/en-us/money/topstocks/renovorx-regains-nasdaq-compliance/ar-AA2aEltp
RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
August 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/21/3349060/0/en/renovorx-regains-compliance-with-nasdaq-minimum-bid-price-requirement.html
RenovoRx Regains Nasdaq Compliance on Minimum Bid Price
August 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/renovorx-regains-nasdaq-compliance-on-minimum-bid-price?utm_source=marketbeat.com&utm_medium=referral
RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
August 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/20/3348338/0/en/renovorx-receives-notice-of-allowance-for-new-u-s-patent-covering-renovocath-an-advanced-dual-occlusion-catheter-for-targeted-therapeutic-drug-delivery-for-cancer-treatment.html
RenovoRx (RNXT) Q2 2026 Earnings Call Transcript
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/renovorx-rnxt-q2-2026-earnings-002829747.html
RenovoRx, Inc. (RNXT) Q2 FY2026 earnings call transcript
August 12, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/quote/RNXT/earnings/RNXT-Q2-2026-earnings_call-669443.html
RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates
August 12, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2973895/renovorx-inc-rnxt-reports-q2-loss-beats-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2973895
RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
August 12, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/renovorx-reports-record-second-quarter-2026-results-driven-by-accelerating-commercial-adoption-and-61-sequential-quarterly-revenue-growth-1036449173
RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
August 11, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/renovorx-achieves-major-milestone-with-full-enrollment-in-phase-iii-tiger-pac-trial-for-locally-advanced-pancreatic-cancer-1036440775

New MarketBeat Followers Over Time

Media Sentiment Over Time

Daxor stock logo

Daxor NASDAQ:DXR

$10.41 -0.05 (-0.48%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$10.42 +0.00 (+0.05%)
As of 10/9/2026 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.

Femasys stock logo

Femasys NASDAQ:FEMY

$2.00 -0.05 (-2.44%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.98 -0.02 (-1.00%)
As of 10/9/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Health Sciences Acquisitions Co. 2 stock logo

Health Sciences Acquisitions Co. 2 NASDAQ:HSAQ

$5.95 +0.22 (+3.84%)
As of 10/9/2026

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

RenovoRx stock logo

RenovoRx NASDAQ:RNXT

$1.28 -0.05 (-3.76%)
Closing price 10/9/2026 04:00 PM Eastern
Extended Trading
$1.30 +0.02 (+1.64%)
As of 10/9/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas